-
1
-
-
0029398377
-
First clinical studies with orlistat: A short review
-
Nov
-
1. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obes Res 1995 Nov; 3 Suppl. 4: 623S-5S
-
(1995)
Obes Res
, vol.3
, Issue.SUPPL. 4
-
-
Drent, M.L.1
Van Der Veen, E.A.2
-
2
-
-
0026604775
-
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro-18-0647 (tetrahydrolipstatin)
-
Jan
-
2. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro-18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992 Jan; 55 Suppl.: 309S-13S
-
(1992)
Am J Clin Nutr
, vol.55
, Issue.SUPPL.
-
-
Hauptman, J.B.1
Jeunet, F.S.2
Hartmann, D.3
-
3
-
-
0024202729
-
Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
-
Dec 1
-
3. Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988 Dec 1; 256: 357-61
-
(1988)
Biochem J
, vol.256
, pp. 357-361
-
-
Hadváry, P.1
Lengsfeld, H.2
Wolfer, H.3
-
4
-
-
0023791240
-
Mode of action of tetrahydrolipstatin: A derivative of the naturally occurring lipase inhibitor lipstatin
-
Oct 14
-
4. Borgström B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988 Oct 14; 962: 308-16
-
(1988)
Biochim Biophys Acta
, vol.962
, pp. 308-316
-
-
Borgström, B.1
-
5
-
-
0028001752
-
Influence of dietary composition on the inhibition of fat absorption by orlistat
-
Sep-Oct
-
5. Güzelhan G, Odink J, Jansen-Zuidema JJ, et al. Influence of dietary composition on the inhibition of fat absorption by orlistat. J Int Med Res 1994 Sep-Oct; 22: 255-65
-
(1994)
J Int Med Res
, vol.22
, pp. 255-265
-
-
Güzelhan, G.1
Odink, J.2
Jansen-Zuidema, J.J.3
-
6
-
-
0027337251
-
Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake
-
Sep
-
6. Hartmann D. Hussain Y, Güzelhan C, et al. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 1993 Sep; 36: 266-70
-
(1993)
Br J Clin Pharmacol
, vol.36
, pp. 266-270
-
-
Hartmann, D.1
Hussain, Y.2
Güzelhan, C.3
-
7
-
-
0030481873
-
Influence of orlistat on the regulation of gallbladder contraction in man: A randomized double-blind placebo-controlled crossover study
-
Dec
-
7. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41: 2404-8
-
(1996)
Dig Dis Sci
, vol.41
, pp. 2404-2408
-
-
Froehlich, F.1
Hartmann, D.2
Guezelhan, C.3
-
8
-
-
0029401358
-
Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects
-
Nov
-
8. Drent ML, Popp-Snijders C, Adèr HJ, et al. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res 1995 Nov; 3: 573-81
-
(1995)
Obes Res
, vol.3
, pp. 573-581
-
-
Drent, M.L.1
Popp-Snijders, C.2
Adèr, H.J.3
-
9
-
-
0009549373
-
Influence of orlistat on gastric emptying rates of fats and solids in healthy subjects
-
Apr 15
-
9. Degen L, Matzinger D, Maecke H, et al. Influence of orlistat on gastric emptying rates of fats and solids in healthy subjects [abstract]. Gastroenterology 1998 Apr 15; 114 (Pt 2 Suppl.): 740
-
(1998)
Gastroenterology
, vol.114
, Issue.PT 2 SUPPL.
, pp. 740
-
-
Degen, L.1
Matzinger, D.2
Maecke, H.3
-
10
-
-
0032924255
-
Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients
-
Jan
-
10. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39: 41-6
-
(1999)
J Clin Pharmacol
, vol.39
, pp. 41-46
-
-
Zhi, J.1
Mulligan, T.E.2
Hauptman, J.B.3
-
11
-
-
0028866609
-
Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers
-
Nov
-
11. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35: 1103-8
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 1103-1108
-
-
Zhi, J.1
Melia, A.T.2
Eggers, H.3
-
13
-
-
0030952712
-
Mode of action of orlistat
-
13. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12-23
-
(1997)
Int J Obes
, vol.21
, Issue.SUPPL. 3
-
-
Guerciolini, R.1
-
14
-
-
8044234962
-
Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers
-
14. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36 (11): 1006-11
-
(1996)
J Clin Pharmacol
, vol.36
, Issue.11
, pp. 1006-1011
-
-
Zhi, J.1
Melia, A.T.2
Funk, C.3
-
15
-
-
0031946729
-
Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Orlistat Dose-Ranging Study Group
-
Apr
-
15. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998 Apr; 54: 125-32
-
(1998)
Eur J Clin Pharmacol
, vol.54
, pp. 125-132
-
-
Van Gaal, L.F.1
Broom, J.I.2
Enzi, G.3
-
16
-
-
0023626926
-
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity
-
Aug
-
16. Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot Tokyo 1987 Aug; 40: 1081-5
-
(1987)
J Antibiot Tokyo
, vol.40
, pp. 1081-1085
-
-
Weibel, E.K.1
Hadvary, P.2
Hochuli, E.3
-
17
-
-
0029762746
-
The effect of tetrahydrolipstatin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
-
Jul
-
17. Zhi J, Melia AT, Guerciolini R, et al. The effect of tetrahydrolipstatin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 659-66
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 659-666
-
-
Zhi, J.1
Melia, A.T.2
Guerciolini, R.3
-
18
-
-
0029059581
-
The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers
-
May
-
18. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35: 521-5
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 521-525
-
-
Zhi, J.1
Melia, A.T.2
Koss-Twardy, S.G.3
-
19
-
-
0033009311
-
Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia
-
Mar
-
19. Oo CY, Akbari B, Lee S. Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest 1999 Mar; 17: 217-23
-
(1999)
Clin Drug Invest
, vol.17
, pp. 217-223
-
-
Oo, C.Y.1
Akbari, B.2
Lee, S.3
-
20
-
-
0029085293
-
The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers
-
Aug
-
20. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995 Aug; 35: 840-3
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 840-843
-
-
Melia, A.T.1
Zhi, J.2
Koss-Twardy, S.G.3
-
21
-
-
0029960012
-
Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL®) in healthy volunteers
-
Apr
-
21. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL®) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36; 352-5
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 352-355
-
-
Melia, A.T.1
Mulligan, T.E.2
Zhi, J.3
-
22
-
-
0029741559
-
The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers
-
Jul
-
22. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 654-8
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 654-658
-
-
Melia, A.T.1
Mulligan, T.E.2
Zhi, J.3
-
24
-
-
0029740253
-
Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers
-
Sep
-
24. Weber C, Tam YK, Schmidtke-Schrezenmeier G. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996 Sep; 51: 87-90
-
(1996)
Eur J Clin Pharmacol
, vol.51
, pp. 87-90
-
-
Weber, C.1
Tam, Y.K.2
Schmidtke-Schrezenmeier, G.3
-
25
-
-
0032441610
-
The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers
-
Nov-Dec
-
25. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998 Nov-Dec; 54: 773-7
-
(1998)
Eur J Clin Pharmacol
, vol.54
, pp. 773-777
-
-
Melia, A.T.1
Zhi, J.2
Zelasko, R.3
-
26
-
-
0029989469
-
The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers
-
Feb
-
26. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36: 152-9
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 152-159
-
-
Zhi, J.1
Melia, A.T.2
Koss-Twardy, S.G.3
-
27
-
-
0029784311
-
The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers
-
Jul
-
27. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 647-53
-
(1996)
J Clin Pharmacol
, vol.36
, pp. 647-653
-
-
Melia, A.T.1
Koss-Twardy, S.G.2
Zhi, J.3
-
28
-
-
0031904104
-
Role of orlistat in the treatment of obese patients with type 2 diabetes
-
Aug
-
28. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998 Aug; 21: 1288-94
-
(1998)
Diabetes Care
, vol.21
, pp. 1288-1294
-
-
Hollander, P.A.1
Elbein, S.C.2
Hirsch, I.B.3
-
29
-
-
0033585499
-
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
-
Jan 20
-
29. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999 Jan 20; 281: 235-42
-
(1999)
JAMA
, vol.281
, pp. 235-242
-
-
Davidson, M.H.1
Hauptman, J.2
DiGirolamo, M.3
-
30
-
-
0032543870
-
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
-
Jul 18
-
30. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998 Jul 18; 352: 167-72
-
(1998)
Lancet
, vol.352
, pp. 167-172
-
-
Sjöström, L.1
Rissanen, A.2
Andersen, T.3
-
31
-
-
0033020351
-
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A I-y study
-
June
-
31. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a I-y study. Am J Clin Nutr 1999 June; 69: 1108-16
-
(1999)
Am J Clin Nutr
, vol.69
, pp. 1108-1116
-
-
Hill, J.O.1
Hauptman, J.2
Anderson, J.W.3
-
32
-
-
85046522762
-
One-year treatment of obesity: A randomised, double-blind, placebo-controlled, multicentre study of orlistat (Xenical®), a gastrointestinal lipase inhibitor
-
In press
-
32. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomised, double-blind, placebo-controlled, multicentre study of orlistat (Xenical®), a gastrointestinal lipase inhibitor. Int J Obes (In press)
-
Int J Obes
-
-
Finer, N.1
James, W.P.2
Kopelman, P.G.3
-
33
-
-
0009485598
-
Two-year study of orlistat in the treatment of obesity
-
Jun 11-14; Minneapolis
-
33. Noack R. Two-year study of orlistat in the treatment of obesity [abstract]. 79th Annual Meeting of the American Endocrine Society: 1997 Jun 11-14; Minneapolis
-
(1997)
79th Annual Meeting of the American Endocrine Society
-
-
Noack, R.1
-
34
-
-
0009542055
-
Orlistat, a gastrointestinal lipase inhibitor, in the long-term treatment of obesity in a primary care setting
-
In press
-
34. Hauptman J, Lucas C, Boldrin M, et al. Orlistat, a gastrointestinal lipase inhibitor, in the long-term treatment of obesity in a primary care setting. Arch Fam Med (In press)
-
Arch Fam Med
-
-
Hauptman, J.1
Lucas, C.2
Boldrin, M.3
-
35
-
-
0028901989
-
Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
-
Apr
-
35. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995 Apr; 19: 221-6
-
(1995)
Int J Obes
, vol.19
, pp. 221-226
-
-
Drent, M.L.1
Larsson, I.2
William-Olsson, T.3
-
36
-
-
0027252448
-
Lipase inhibition; a novel concept in the treatment of obesity
-
36. Drent ML, van der Veen EA. Lipase inhibition; a novel concept in the treatment of obesity. Int J Obes 1993; 17: 241-4
-
(1993)
Int J Obes
, vol.17
, pp. 241-244
-
-
Drent, M.L.1
Van Der Veen, E.A.2
-
37
-
-
0009519113
-
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
-
In press
-
37. Rössner S, Sjöstrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res (In press)
-
Obes Res
-
-
Rössner, S.1
Sjöstrom, L.2
Noack, R.3
-
38
-
-
4243955566
-
Early weight loss with orlistat as a predictor of long-term success in obesity treatment
-
abstract no. 577
-
38. Rissanen A, Sjöström L, Rössner S. Early weight loss with orlistat as a predictor of long-term success in obesity treatment [abstract no. 577]. Int J Obes 1999; 23 Suppl. 5: S174
-
(1999)
Int J Obes
, vol.23
, Issue.SUPPL. 5
-
-
Rissanen, A.1
Sjöström, L.2
Rössner, S.3
-
39
-
-
4243835827
-
Health-related quality of life (HRQoL) during treatment with orlistat (Xenical®)
-
[abstract no. 518]. May
-
39. Stolshek B, Mathias S, Pasta D, et al. Health-related quality of life (HRQoL) during treatment with orlistat (Xenical®) [abstract no. 518]. Int J Obes 1999 May; 23 Suppl. 5: S158
-
(1999)
Int J Obes
, vol.23
, Issue.SUPPL. 5
-
-
Stolshek, B.1
Mathias, S.2
Pasta, D.3
-
40
-
-
0344334027
-
Pharmacological treatment of obesity; present status
-
Feb
-
40. Scheen AJ, Leféhvre PJ. Pharmacological treatment of obesity; present status. Int J Obes 1999 Feb; 23 Suppl. 1: 47-53
-
(1999)
Int J Obes
, vol.23
, Issue.SUPPL. 1
, pp. 47-53
-
-
Scheen, A.J.1
Leféhvre, P.J.2
-
41
-
-
0028239543
-
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia
-
41. Tonstad S, Pometta D. Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46 (5): 405-10
-
(1994)
Eur J Clin Pharmacol
, vol.46
, Issue.5
, pp. 405-410
-
-
Tonstad, S.1
Pometta, D.2
Erkelens, D.W.3
-
42
-
-
0000176091
-
Orlistat-induced weight loss improves response to oral glucose tolerance testing
-
[abstract no. P677]. Aug
-
42. Rissanen A. Orlistat-induced weight loss improves response to oral glucose tolerance testing [abstract no. P677]. Int J Obes 1998 Aug; 22 Suppl. 3: S274
-
(1998)
Int J Obes
, vol.22
, Issue.SUPPL. 3
-
-
Rissanen, A.1
-
43
-
-
0027254665
-
Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus
-
Jul
-
43. Watkins PJ. Joint Working Party of the British Diabetic Association, the Research Unit of the Royal College of Physicians, and the Royal College of General Practitioners, Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. J R Coll Physicians Lond 1993 Jul; 27 (3): 259-66
-
(1993)
J R Coll Physicians Lond
, vol.27
, Issue.3
, pp. 259-266
-
-
Watkins, P.J.1
-
44
-
-
4243449580
-
Effect of treatment with orlistat for one-year on blood pressure in obese patients
-
abstract no. 582
-
44. Pataky Z, Golay A. Effect of treatment with orlistat for one-year on blood pressure in obese patients [abstract no. 582]. Int J Obes 1999; 23 Suppl. 5: S175
-
(1999)
Int J Obes
, vol.23
, Issue.SUPPL. 5
-
-
Pataky, Z.1
Golay, A.2
-
45
-
-
0009483863
-
-
Hoffman-La Roche, Nutley (NJ), Data on file
-
45. Lucas C, Hauptman J, Boldrin M, et al. Effect of orlistat on weight loss and cardiovascular disease risk factors in obese hypertensive patients. Hoffman-La Roche, Nutley (NJ), 1999. (Data on file)
-
(1999)
Effect of Orlistat on Weight Loss and Cardiovascular Disease Risk Factors in Obese Hypertensive Patients
-
-
Lucas, C.1
Hauptman, J.2
Boldrin, M.3
-
46
-
-
0001450312
-
Long-term tolerability profile of orlistat, an intestinal lipase inhibitor
-
[abstract no. 769]. Jun
-
46. Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract no. 769]. Diabetologia 1997 Jun; 40 Suppl. 1: A196
-
(1997)
Diabetologia
, vol.40
, Issue.SUPPL. 1
-
-
Canovatchel, W.1
-
50
-
-
0031974818
-
Overweight and obesity in the United Slates: Prevalence and trends, 1960-1994
-
Jan
-
50. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United Slates: prevalence and trends, 1960-1994. Int J Obes 1998 Jan; 22 (1); 39-47
-
(1998)
Int J Obes
, vol.22
, Issue.1
, pp. 39-47
-
-
Flegal, K.M.1
Carroll, M.D.2
Kuczmarski, R.J.3
-
51
-
-
0032911574
-
The burden of obesity and its sequelae
-
Jan
-
51. Seidell JC. The burden of obesity and its sequelae. Dis Manage Health Outcomes 1999 Jan; 5: 13-21
-
(1999)
Dis Manage Health Outcomes
, vol.5
, pp. 13-21
-
-
Seidell, J.C.1
-
52
-
-
0032554512
-
Impairment of health and quality of life in people with large waist circumference
-
Mar 21
-
52. Lean MEJ, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet 1998 Mar 21; 351: 853-6
-
(1998)
Lancet
, vol.351
, pp. 853-856
-
-
Lean, M.E.J.1
Han, T.S.2
Seidell, J.C.3
-
53
-
-
0031034579
-
Waist circumference reduction and cardiovascular benefits during weight loss in women
-
53. Han TS, Richmond P, Avenell A, et al. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes 1997; 21: 127-34
-
(1997)
Int J Obes
, vol.21
, pp. 127-134
-
-
Han, T.S.1
Richmond, P.2
Avenell, A.3
-
54
-
-
0032575852
-
Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults
-
Sep 28
-
54. Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998 Sep 28; 158: 1855-67
-
(1998)
Arch Intern Med
, vol.158
, pp. 1855-1867
-
-
-
55
-
-
0029366646
-
Guidelines for the approval and use of drugs to treat obesity - A position paper of the North American Association for the Study of Obesity
-
Sep
-
55. Pi-Sunyer X. Guidelines for the approval and use of drugs to treat obesity - a position paper of the North American Association for the Study of Obesity. Obes Res 1995 Sep; 3: 473-8
-
(1995)
Obes Res
, vol.3
, pp. 473-478
-
-
Pi-Sunyer, X.1
-
56
-
-
1842365433
-
Effects of weight loss und sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure
-
56. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss und sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med 1497; 157: 657-67
-
(1497)
Arch Intern Med
, vol.157
, pp. 657-667
-
-
-
58
-
-
0033549087
-
The safety of newly approved medicines: Do the recent market removals mean there is a problem?
-
58. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do the recent market removals mean there is a problem? JAMA 1999; 281: 1728-34
-
(1999)
JAMA
, vol.281
, pp. 1728-1734
-
-
Friedman, M.A.1
Woodcock, J.2
Lumpkin, M.M.3
-
59
-
-
0032448213
-
Orlistat: A novel concept in the treatment of obesity
-
Nov
-
59. Goldenberg MM, Caspi A. Orlistat: a novel concept in the treatment of obesity. PT 1998 Nov; 23: 571-80
-
(1998)
PT
, vol.23
, pp. 571-580
-
-
Goldenberg, M.M.1
Caspi, A.2
-
60
-
-
0032434821
-
Sibutramine: A review of its contribution to the management of obesity
-
Dec
-
60. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998 Dec; 56: 1093-124
-
(1998)
Drugs
, vol.56
, pp. 1093-1124
-
-
McNeely, W.1
Goa, K.L.2
-
61
-
-
0001999204
-
Long-term weight loss with sibutramine
-
61. Jones SP, Smith IG, Kelly F, et al. Long-term weight loss with sibutramine [abstract]. Int J Obes 1995; 19 Suppl. 2: 41
-
(1995)
Int J Obes
, vol.19
, Issue.SUPPL. 2
, pp. 41
-
-
Jones, S.P.1
Smith, I.G.2
Kelly, F.3
-
63
-
-
0032569321
-
Flushing away the fat
-
Sep 26
-
63. Garrow J. Flushing away the fat. BMJ 1998 Sep 26; 317: 830-1
-
(1998)
BMJ
, vol.317
, pp. 830-831
-
-
Garrow, J.1
-
64
-
-
0032585133
-
Orlistat and weight loss
-
Oct 31
-
64. McCarthy WJ. Orlistat and weight loss [letter]. Lancet 1998 Oct 31; 352: 1473
-
(1998)
Lancet
, vol.352
, pp. 1473
-
-
McCarthy, W.J.1
|